10-15 million Americans have undiagnosed / asymptomatic brain aneurysms. We are creating a new alternative device to improve outcomes of patients treated for ruptured and unruptured cerebral aneurysms with our cPAX embolization strand.
Read More
The cPAX system uses existing neurovascular procedural techniques with notable differences that set it apart from traditional platinum coils and other IA treatment devices.
Read More
Existing intracranial aneurysm (IA) coiling procedure codes will likely be applicable to cPAX, and use of the cPAX strand can reduce overall required inventory requirements and costs when compared to platinum coils.
Read More
The current worldwide market for neurovascular technology is expected to reach $3.8 billion USD by 2026 with a CAGR of 6.4% annually. Of the varied neurovascular treatments embolics comprise 42.5% of the total neurovascular device market or, $1.62 billion and growing.
Read More
NeuroVASx, Inc. is led by Steve Ferry who acquired and refounded NeuroVASx in 2014, and his management team, board of directors, and medical advisory board. Since 2014, NeuroVASx has made great strides in creating the necessary technology and formulating the studies to improve aneurysm outcomes. cPAX continues to advance with patents both pending and issued, along with peer testimonials from doctors across the nation.
View NeuroVASx Team, Patents, & Testimonials
Through strong leadership and thorough medical and industrial application knowledge, cPAX has become what it is today - the next step in the evolution from using platinum coils in cerebral aneurysm embolization. Patients, physicians, administrators, and investors alike can learn more about neurovascular aneurysms, treatments, the science behind it, the future of the market, along with regulatory requirements around this method of treatment.
Learn More About cPAX System & Coils